NeoStem's Cancer Immunotherapy Experts to Present at Novel Cancer Therapeutics Summit 2014
June 30 2014 - 7:45AM
NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular
therapy industry, announced today that two of its leading cancer
immunotherapy experts, Dr. Andrew Pecora, Chief Visionary Officer,
NeoStem; and Dr. Robert O. Dillman, Vice President, Oncology of the
Company's wholly-owned subsidiary, NeoStem Oncology LLC., will give
presentations at the sub-conferences of the Novel Cancer
Therapeutics Summit in Boston, Massachusetts on Monday, July 7.
Dr. Pecora will speak about highlights of NeoStem's Targeted
Immunotherapy Program that focuses on patient-specific
immunotherapies for the treatment of late stage cancers, including
NeoStem's expected launch later this year of a pivotal Phase 3
trial for Melapuldencel-T, its lead product candidate. Dr. Dillman
will speak about whether the best source of tumor-associated
antigens may be autologous tumor cells that self-renew in tissue
culture.
3rd Annual Oncology Partnering and Deal
Making
- Date and Time: Monday, July 7, 2014, 5:05 PM
EDT
- Venue: Hyatt Regency, Boston, MA
- Website:
https://www.gtcbio.com
- Presenter: Dr. Andrew Pecora, Chief Visionary
Officer, NeoStem
- Topic: Targeting Cancer Initiating Cells With
a Novel Immunotherapy
5th Annual Cancer Targets and Therapeutics
- Date and Time: Monday, July 7, 2014, 2:30 PM
EDT
- Venue: Hyatt Regency, Boston, MA
- Website:
https://www.gtcbio.com
- Presenter: Dr. Robert O. Dillman, Vice
President, Oncology, NeoStem Oncology
- Topic: Tumor Stem Cell Antigen-based
Patient-Specific Therapeutic Vaccines in Metastatic Melanoma
About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry,
pursuing the preservation and enhancement of human health globally
through the development of cell based therapeutics that prevent,
treat or cure disease by repairing and replacing damaged or aged
tissue, cells and organs and restoring their normal function. The
business includes the development of novel proprietary cell therapy
products as well as a revenue-generating contract development and
manufacturing service business. This combination has created an
organization with unique capabilities for cost effective in-house
product development and immediate revenue and cash flow generation.
www.neostem.com
About Melapuldencel-T
NeoStem expects to initiate a pivotal Phase 3 trial for
Melapuldencel-T, an autologous melanoma initiating (stem) cell
immune based therapy intended to eliminate the tumor cells capable
of causing disease recurrence. The goal of the therapy is to
eliminate or neutralize the tumor cells that are responsible for
recurrence after medically induced tumor regression after a patient
has already had undergone other treatments which may have reduced
tumor size, but failed to entirely eliminate the cancer.
Melapuldencel–T has been the subject of compelling trial results
for the treatment of metastatic melanoma. As a result,
Melapuldencel-T has been approved to enter a Phase 3 clinical trial
with Special Protocol Assessment (SPA) and received Fast Track
designation for metastatic melanoma, as well as Orphan Drug
designation.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward-looking statements include
statements herein with respect to the successful execution of the
Company's business strategy, the Company's ability to develop and
grow its business, the successful development of cellular therapies
with respect to the Company's research and development and clinical
evaluation efforts in connection with the Company's Targeted
Immunotherapy Program (including whether or not Melapuldencel-T
will successfully be developed to treat metastatic melanoma or any
other cancer indications), CD34 Cell Program, T Regulatory Cell
Program and other cell therapies, the future of the regenerative
medicine industry and the role of stem cells and cellular therapy
in that industry and the performance and planned expansion of the
Company's contract development and manufacturing business. The
Company's actual results could differ materially from those
anticipated in these forward-looking statements as a result of
various factors. Factors that could cause future results to
materially differ from the recent results or those projected in
forward-looking statements include the "Risk Factors" described in
the Company's Annual Report on Form 10-K filed with the Securities
and Exchange Commission ("SEC") on March 13, 2014, the Company's
Current Report on Form 8-K filed with the SEC on May 8, 2014 and in
the Company's other periodic filings with the SEC. The Company's
further development is highly dependent on future medical and
research developments and market acceptance, which is outside its
control.
CONTACT: Investor Contact:
LifeSci Advisors, LLC
Michael Rice
Founding Partner
Phone: +1-646-597-6979
Email: mrice@lifesciadvisors.com
Media Contact:
NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jun 2024 to Jul 2024
NeoStem, Inc. (NASDAQ:NBS)
Historical Stock Chart
From Jul 2023 to Jul 2024